Received Mar 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| IPV | POLIO VIRUS, INACT. (IPOL) | SANOFI PASTEUR | UNK | WIC741M | OT |
ipol was administered instead of tubersol with no reported adverse event; patient received 0.1cc of IPOL intradermally with no reported adverse event; Initial information received on 25-Feb-2025 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 47 years old female patient who received IPV (VERO) [IPOL] instead of tuberculin test [Tubersol] and received intradermally with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On an unknown date, the patient started taking dosage unknown route unknown for Tuberculin test. On 25-Feb-2025, the patient received 0.1 cc of IPV (VERO) Suspension for injection with standard strength (expiry date- 17-NOV-2025 and lot WIC741M) once via intradermal route in the left forearm (incorrect route of product administration) for Immunization instead of Tuberculin test Solution for injection with strength- 5-TU (Tuberculin unit) (lot and expiry date- unknown) (wrong product administered) with no reported adverse event (latency- same day). Reportedly, patient visited the ER (Emergency room) right after receiving IPOL and no adverse event was reported. Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.